AbbVie’s immunology franchise generated roughly $14 billion in 2024, yet the company is placing its Canadian ecosystem bet on a startup that has existed for less than 18 months. That tension — megacap pharma cultivating a one-year-old peptide discovery shop — is the actual story behind the AbbVie Biotech Innovators Award landing with RIME Therapeutics, a Montreal company spun out of Amplitude Ventures’ Pre-Amp studio.
What RIME is building matters more than the prize itself. The Disruptide Platform attacks protein-protein interactions — historically the graveyard of small-molecule drug discovery — by collapsing target identification and hit generation into a single workflow. Most platforms force a sequential handoff: find the biology, then spend years hunting chemistry that can address it. RIME claims to run those steps simultaneously, using human genetics, perturbation biology, and AI to scan functional pocket space and return tractable chemical matter in the same motion. The therapeutic focus is T cell biology in inflammation and immunology, which places RIME directly in AbbVie’s core competency and squarely in the post-Humira diversification problem AbbVie has been spending aggressively to solve.
The award itself — lab and office space at the adMare Innovation Centre plus AbbVie scientific and business mentorship for one year — is modest in dollar terms. But the strategic subtext is not. AbbVie gets early visibility into a platform technology operating in its primary disease space, under favorable conditions, before any Series A pricing pressure. adMare, which has built 39 companies attracting $2.5 billion in risk capital, provides the infrastructure credibility that makes the arrangement functional rather than ceremonial. For RIME, the mentorship access to AbbVie’s drug hunters is likely worth more than the real estate; learning how a top-five immunology company evaluates mechanism-of-action risk shapes how a seed-stage team prioritizes its own pipeline decisions.
The marker to track is whether RIME surfaces a disclosed development candidate within the award window. A named target or lead series would signal that the Disruptide Platform’s simultaneous discovery-and-validation claim holds under real experimental pressure — and would immediately reframe AbbVie’s involvement from goodwill sponsorship to de facto option on the asset.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
